Vladimir Perkov

Vladimir Perkov

Auto-generated profile, based on publicly available information

Vladimir Perkov

Sanofi, Marcy-l’Étoile, France

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 May 2022 in Biomaterials
Verified
Journal Article
Open access
MRManon Ripoll
Manon Ripoll
MBMarie-Clotilde Bernard
Marie-Clotilde Bernard
CVCéline Vaure
Céline Vaure
EBEmilie Bazin
Emilie Bazin
SCSylvie Commandeur
Sylvie Commandeur
JHJean Haensler
Jean Haensler
The mRNA vaccine technology has promising applications to fight infectious diseases as demonstrated by the licensing of two mRNA-based vaccines, Comirnaty® (Pfizer/BioNtech) and Spikevax® (Moderna), in the context of the Covid-19 crisis. Safe and effective delivery systems are essential to the performance of these vaccines and lipid nanoparticles (LNPs) able to entrap, protect and deliver the mRNA in vivo are considered by many as the current “best in class”. Nevertheless, current mRNA/LNP vaccine technology has still some limitations, one of them being thermostability, as evidenced by the ultracold distribution chain required for the licensed vaccines. We found that the thermostability of mRNA/LNP, could be improved by a novel imidazole modified lipid, DOG-IM4, in combination with standard helper lipids. DOG-IM4 comprises an ionizable head group consisting of imidazole, a dioleoyl lipid tail and a short flexible polyoxyethylene spacer between the head and tail. Here we describe the synthesis of DOG-IM4 and show that DOG-IM4 LNPs confer strong immunization properties to influenza HA mRNA in mice and macaques and a remarkable stability to the encapsulated mRNA when stored liquid in phosphate buffered saline at 4 °C. We speculate the increased stability to result from some specific attributes of the lipid's imidazole head group.

20 June 2024 in npj Vaccines
Verified
Journal Article
Open access
PDF file
KLKatia Lemdani
Katia Lemdani
RMRomain Marlin
Romain Marlin
CMCéline Mayet
Céline Mayet
VPVladimir Perkov
Vladimir Perkov
QPQuentin Pascal
Quentin Pascal
RGRoger Le Grand
Roger Le Grand
The characterization of vaccine distribution to relevant tissues after in vivo administration is critical to understanding their mechanisms of action. Vaccines based on mRNA lipid nanoparticles (LNPs) are now being widely considered against infectious diseases and cancer. Here, we used in vivo imaging approaches to compare the trafficking of two LNP formulations encapsulating mRNA following intramuscular administration: DLin-MC3-DMA (MC3) and the recently developed DOG-IM4. The mRNA formulated in DOG-IM4 LNPs persisted at the injection site, whereas mRNA formulated in MC3 LNPs rapidly migrated to the draining lymph nodes. Furthermore, MC3 LNPs induced the fastest increase in blood neutrophil counts after injection and greater inflammation, as shown by IL-1RA, IL-15, CCL-1, and IL-6 concentrations in nonhuman primate sera. These observations highlight the influence of the nature of the LNP on mRNA vaccine distribution and early immune responses.

18 September 2023 in Journal of Applied Toxicology
Verified
Journal Article
Open access
KBKarine Broudic
Karine Broudic
SLSébastien Laurent
Sébastien Laurent
VPVladimir Perkov
Vladimir Perkov
CSCharlene Simon
Charlene Simon
MGMarie Garinot
Marie Garinot
PDPaul Désert
Paul Désert
Messenger RNA (mRNA) vaccines have demonstrated efficacy against Severe Acute Respiratory Syndrome Coronavirus‐2 (SARS‐CoV‐2) in humans. mRNA technology holds tremendous potential for rapid control and prevention of emergencies due to its flexibility with respect to production, application, and design for an efficacious and safe use in humans. We assessed the toxicity and biodistribution of MRT5500, an mRNA vaccine encoding for the full‐length of the SARS‐CoV‐2 spike protein and delivered by lipid nanoparticles (LNPs) containing a novel ionizable lipid, Lipid‐1 in preclinical animal models. In the repeated dose toxicity study, rabbits received three intramuscular (IM) injections of MRT5500 at 3‐week interval followed by a 4‐week observation period. In an exploratory biodistribution study in mice receiving a single IM injection of an mRNA encoding luciferase encapsulated in an LNP containing Lipid‐1, the expression of the luciferase protein was monitored in vivo and ex vivo at several time points. In the regulatory biodistribution study in rabbits receiving a single IM injection of MRT5500, the quantification of the mRNA and the ionizable Lipid‐1 were monitored in the same organs and time points as in the exploratory biodistribution study. MRT5500 was safe and well‐tolerated with a transient acute phase response/inflammation and an expected vaccine‐related immunological response, typical of those observed following a vaccine administration. The biodistribution data demonstrated that the mRNA and Lipid‐1 components of the vaccine formulations were mainly detected at the injection site and in the draining lymph nodes. These results support the use of MRT5500 and its deployment into clinical trials.